Current Report Filing (8-k)
November 14 2017 - 9:02AM
Edgar (US Regulatory)
United
States
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 14, 2017
CHINA
JO-JO DRUGSTORES, INC.
(Exact
name of Registrant as specified in charter)
Nevada
|
|
001-34711
|
|
98-0557852
|
(State
or other jurisdiction
of Incorporation)
|
|
(Commission
File No.)
|
|
(IRS
Employer
Identification No.)
|
1st
Floor, Yuzheng Plaza, No. 76, Yuhuangshan Road
Hangzhou,
Zhejiang Province, People’s Republic of China, 310002
(Address
of principal executive offices) (Zip Code)
Registrant's
telephone number, including area code:
+86 (571) 88077078
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the
Securities Act (17CFR230.425)
|
|
|
☐
|
Soliciting material pursuant to Rule14a-12 under the
Exchange Act (17CFR240.14a-12)
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17CFR240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
2.02. Results of Operations and Financial Condition.
On
November 14, 2017, China Jo-Jo Drugstores, Inc. (the “Company”) issued a press release announcing certain financial
results for the fiscal quarter ended September 30, 2017. A copy of the press release is attached hereto as Exhibit 99.1.
This
information under this Item 2.02 and the press release attached to this Form 8-K as Exhibit 99.1 shall be deemed to be “furnished”
and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), or otherwise subject to the liabilities under that section and shall not be deemed incorporated by
reference in any filing under the Exchange Act or the Securities Act of 1933, as amended.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
The
following is filed as an exhibit to this report:
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
CHINA
JO-JO DRUGSTORES, INC.
|
|
|
|
Date:
November 14, 2017
|
By:
|
/s/
Ming Zhao
|
|
Name:
|
Ming
Zhao
|
|
Title:
|
Chief
Financial Officer
|
3
China Jo Jo Drugstores (NASDAQ:CJJD)
Historical Stock Chart
From Mar 2024 to Apr 2024
China Jo Jo Drugstores (NASDAQ:CJJD)
Historical Stock Chart
From Apr 2023 to Apr 2024